ERBB2 and breast cancer: In our study, the TNBC subtype had the highest proportion of patients with a family history of BC and ovarian cancer (22.2% and 11.1%, respectively), followed by patients in the Luminal A and Luminal B subtypes, with rates of 19.3%/3.8%, and 12.5%/3.1%, respectively, with the lowest in the HER2-enriched subtype with 6.7% and 0% (Table 1).